Pfiz­er lays down its hand on Chi­nese biosims, of­fload­ing its 3-year-old plant to WuXi Bi­o­log­ics as com­pe­ti­tion grows

Pfiz­er is in down­siz­ing mode af­ter a hefty spin­off of its Up­john gener­ics unit and a full-scale piv­ot to­ward brand­ed meds. That move left Pfiz­er’s biosim unit in lim­bo, and now the drug­mak­er is mak­ing an ear­ly ex­it from the Chi­nese mar­ket as it faces a slate of un­ex­pect­ed com­peti­tors.

Pfiz­er has ef­fec­tive­ly bailed on its shot at the Chi­nese biosim­i­lars mar­ket by of­fload­ing its three-year-old plant in Hangzhou to WuXi Bi­o­log­ics, the Chi­nese firm said ear­li­er this week.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER